Novacek G, Miehsler W, Wrba F, Ferenci P, Penner E, Vogelsang H
Department of Internal Medicine IV, University of Vienna, Austria.
Eur J Gastroenterol Hepatol. 1999 Mar;11(3):283-8. doi: 10.1097/00042737-199903000-00012.
To assess the prevalence and potential pathogenetic factors of hypertransaminasaemia in patients with coeliac disease prior to initiation of a gluten-free diet (GFD) and to assess the course of transaminases on a GFD.
A retrospective study was made of 178 patients with coeliac disease (130 women, 48 men; median age 36 years; range 17-84 years) at the gastroenterological department of a university hospital.
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were measured prior to initiation of a GFD and at 3, 6 and 12 months of GFD. Intestinal permeability, a test for functional integrity of the small bowel, was investigated before starting a GFD in 116 patients by an oral test using lactulose and mannitol.
In 72 patients (40.4%) AST and/or ALT were increased prior to initiation of a GFD. Within 1 year on a GFD ALT and AST normalized except in eight cases (4.6%). The intestinal permeability index (% lactulose/% mannitol in 5 h urine) was higher in patients with elevated (median 0.34; range 0.03-1.43) than in patients with normal transaminases (0.11; 0.02-1.28) (P < 0.0001) and correlated with AST (tau = 0.34; P < 0.0001) and ALT (tau = 0.32; P < 0.0001). In five cases with hypertransaminasaemia a liver biopsy was performed prior to initiation of a GFD. Two patients had mild to moderate hepatitis with septal fibrosis. The other three had minimal lymphocytic infiltrates of the portal tracts. Inflammatory alterations of the bile ducts were not found.
Hypertransaminasaemia before GFD is frequent in coeliac patients, correlates with intestinal permeability and normalizes on a GFD in most patients. In cases of persistently elevated liver function tests of unknown origin underlying coeliac disease should be considered.
评估乳糜泻患者在开始无麸质饮食(GFD)之前高转氨酶血症的患病率和潜在致病因素,并评估在GFD治疗下转氨酶的变化过程。
对一家大学医院胃肠病科的178例乳糜泻患者(130名女性,48名男性;中位年龄36岁;范围17 - 84岁)进行了一项回顾性研究。
在开始GFD之前以及GFD治疗3、6和12个月时测量天冬氨酸转氨酶(AST)和丙氨酸转氨酶(ALT)。在116例患者开始GFD之前,通过口服乳果糖和甘露醇的试验研究小肠功能完整性的肠通透性测试。
在开始GFD之前,72例患者(40.4%)的AST和/或ALT升高。在GFD治疗1年内,除8例(4.6%)外,ALT和AST恢复正常。转氨酶升高的患者(中位值0.34;范围0.03 - 1.43)的肠通透性指数(5小时尿液中乳果糖/甘露醇的百分比)高于转氨酶正常的患者(0.11;0.02 - 1.28)(P < 0.0001),并且与AST(tau = 0.34;P < 0.0001)和ALT(tau = 0.32;P < 0.0001)相关。在5例高转氨酶血症患者中,在开始GFD之前进行了肝活检。2例患者患有轻度至中度肝炎伴间隔纤维化。另外3例患者门静脉区有轻度淋巴细胞浸润。未发现胆管的炎症改变。
乳糜泻患者在GFD之前高转氨酶血症很常见,与肠通透性相关,并且在大多数患者中在GFD治疗下恢复正常。在肝功能检查持续升高且病因不明的情况下,应考虑潜在的乳糜泻。